Intracavitary Therapeutics for Pleural Malignancies

Vivek Murthy; Keshav Mangalick; Daniel H Sterman

doi:10.1016/j.ccm.2017.11.003

Intracavitary Therapeutics for Pleural Malignancies

Clin Chest Med. 2018 Mar;39(1):195-209. doi: 10.1016/j.ccm.2017.11.003. Epub 2017 Dec 13.

Authors

Vivek Murthy¹, Keshav Mangalick¹, Daniel H Sterman²

Affiliations

¹ NYU PORT (Pulmonary Oncology Research Team), Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, NYU Langone Health, 550 First Avenue Suite 5D, New York, NY 10016, USA.
² NYU PORT (Pulmonary Oncology Research Team), Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, NYU Langone Health, 550 First Avenue Suite 5D, New York, NY 10016, USA. Electronic address: Daniel.sterman@nyumc.org.

PMID: 29433715
DOI: 10.1016/j.ccm.2017.11.003

Abstract

Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

Keywords: Intracavity therapeutics; Mesothelioma; Pleural malignancies; Pleural space.

Publication types

Review

MeSH terms

Combined Modality Therapy / methods*
Female
Humans
Male
Mesothelioma / pathology
Mesothelioma / therapy*
Pleural Neoplasms / pathology
Pleural Neoplasms / therapy*